Aurum Biosciences Ltd is a UK based clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and Inflammation Imaging. Follow-on indications include heart disease, cardiac arrest, oncology, spinal cord injury (SCI), and traumatic brain injury (TBI).

Only about 10% of patients suffering from acute stroke — the world’s second biggest killer and leading cause of disability — are able to access current therapeutics, significantly impacting their outcomes in time-critical situations.

Aurum’s patented ABL-101 platform technology has the potential to dramatically change that for the overwhelming 90% of patients currently missing out during emergencies through its promise to help treat the stroke-related oxygen deprivation which can quickly cause brain damage.

Aurum’s lead product ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. ABL-101, is planned for phase 2 trials in stroke and inflammation imaging in 2026